 |
 |
 |
 |
 |
|
|
|
|
|
A "next-generation" ester ophthalmic steroid, Lotemax® targets inflammation with a unique, site-active mechanism of action. Structural modifications associated with an ester ophthalmic steroid make Lotemax highly lipid soluble, enhancing its penetration into cells and enabling Lotemax to exert anti-inflammatory activity within the eye.2-6
Lotemax is indicated for the treatment of steroid responsive inflammatory conditions associated with the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. In clinical studies, Lotemax resolved or controlled inflammation in 95% of post-operative patients following cataract surgery,9 vs. 65% for placebo. Lotemax has also been proven effective for giant papillary conjunctivitis.10, 11 No other ophthalmic steroid has as broad an array of indications1 as Lotemax.
Moreover, in known corticosteroid responders, studies have shown that patients treated with Lotemax demonstrate a low incidence of clinically significant, increased IOP.12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Unique site-active mechanism of action |
|
|
|
|
|
Cells and flare resolved or mild in 95% of patients by final visit vs. 65% placebo in post-operative cases9 |
|
|
|
|
|
Broad array of FDA approved indications1 |
|
|
|
|
|
Low incidence of increased IOP |
|
|
|
|
|
|
|
|
|
|
|
As with other ophthalmic corticosteroids, Lotemax is contraindicated in most viral diseases of the cornea and conjunctiva and in mycobacterial and fungal diseases of the eye. Prolonged use may result in secondary glaucoma, cataract formation, and secondary ocular infections following suppression of the host response and/or perforation of the globe. The most common adverse events in patients treated with Lotemax were abnormal vision/blurring, burning, chemosis, discharge, and dry eyes. |
|
|
|
|
|
|
|
|
|
If you would like more information about this product, or to put in a request for samples of Lotemax, please call 1-800-323-0000. |
|
|
|
|
|
